On Wednesday, Shares of JPMorgan Chase & Co. (NYSE:JPM), lost -1.45% to $67.24.
JPMorgan Chase & Co. Asset Management - Global Real Assets declared the appointment of Alexia Gottschalch as Head of Business Development and Client Strategy, Real Estate Americas, a new position. In this capacity, Ms. Gottschalch will lead the team responsible for raising capital and advising clients for the firm’s Real Estate Americas investment platform with $54 billion in gross assets under administration and 220 professionals. She will be based in New York and will report to Doug Doughty, Global Head of Business Development at J.P. Morgan Asset Administration – Global Real Assets.
Real Estate Americas is part of J.P. Morgan Asset Administration – Global Real Assets, a real assets investment platform founded in 1970 with more than $85 billion in assets under administration, 400-plus professionals and leadership positions in real estate, infrastructure and maritime investing across the Americas, Europe and Asia Pacific. Real Estate Americas is a leader in core, core-plus, value add and opportunistic U.S. real estate equity investing for both U.S. and non-U.S. institutions, in addition to an innovator in incorporating direct real estate investments in defined contribution solutions. Among its fund line-up is the industry’s largest U.S. core real estate commingled fund, JPMCB Planned Property Fund, with $25.6 billion in net asset value.
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Management.
Shares of Caterpillar Inc. (NYSE:CAT), inclined 1.13% to $78.92, during its last trading session.
Caterpillar will offer a one-hour audio webcast of a teleconference with financial analysts and institutional shareholders to be held on Wednesday, August 19, 2015, at 2 p.m. Central Time.
Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives worldwide.
Finally, Opko Health, Inc. (NYSE:OPK), ended its last trade with no change, and closed at $13.45.
OPKO Health on Wednesday stated a loss of $42.8 million in its second quarter, according to AP.
The Miami-based company said it had a loss of 9 cents per share. Losses, adjusted for non-recurring costs, came to 4 cents per share.
The holding company with investments in pharmaceutical and diagnostics companies posted revenue of $42.4 million in the period. AP Reports
OPKO Health shares have climbed 61 percent since the starting of the year. In the final minutes of trading on Wednesday, shares hit $16.11, a rise of 81 percent in the last 12 months. AP added.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
